Darcy Mootz, Ph.D., currently serves as President of Architect Therapeutics, a position she has held since April 2023. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations. She previously served as Head of Amunix Pharmaceuticals from February 2022 until April 2023 and was Chief Business Officer of Amunix from February 2019 to February 2022. Prior to joining Amunix, Dr. Mootz was an independent consultant working with venture capital firms and life sciences companies on corporate development and strategy projects. Before that, she served as Chief Business Officer of ORIC Pharmaceuticals, and, earlier, served as Vice President, Corporate Development at Achaogen. In addition to the Elevation Oncology Board, Dr. Mootz also serves on the Board of Directors of Alpha-9 Oncology.
Dr. Mootz received a B.S. in Biology from Duke University and a Ph.D. in Biochemistry from Harvard University.